INT207727

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.94
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (SRY) nucleus (SRY) DNA binding (SRY)
transcription factor binding (SRY) cytoplasm (SRY)
Anatomy Link Frequency
plasma 1
SRY (Homo sapiens)
Pain Link Frequency Relevance Heat
peripheral neuropathy 2 50.88 Quite High
Potency 8 5.00 Very Low Very Low Very Low
ischemia 4 5.00 Very Low Very Low Very Low
Bioavailability 4 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Spinal cord 1 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
medulla 1 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Nephrotoxicity 2 97.92 Very High Very High Very High
Chronic Renal Failure 2 88.60 High High
Metastasis 51 86.56 High High
Cancer 36 86.12 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 72 82.24 Quite High
Prostate Cancer 55 81.12 Quite High
Renal Disease 4 81.08 Quite High
Hyperkalemia 2 79.00 Quite High
Glycosuria 4 78.08 Quite High
Hypophosphatemia 2 76.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As mentioned above, co-administration of TDF with certain protease inhibitors, including atazanavir, lopinavir/ritonavir, and darunavir (TMC-114)/ritonavir (Hoetelmans et al 2007) results in increased plasma levels of TDF and, in the case of atazanavir and lopinavir/ritonavir, reduced protease inhibitor troughs.
Positive_regulation (increased) of TDF in plasma
1) Confidence 0.56 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 0.29 Pain Relevance 0.03
Because certain protease inhibitors, including lopinavir and atazanavir, increase the serum levels of TDF by as much as 25%, this could be a risk factor for nephrotoxicity (Kiser et al 2007; Goicoechea et al 2007), and extra caution is advised.
Positive_regulation (increase) of TDF associated with nephrotoxicity
2) Confidence 0.56 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 0.94 Pain Relevance 0
Similarly, a large number of transcription factors (67) including AR, SRY, FOS and EGR3, are differentially expressed.
Positive_regulation (including) of SRY
3) Confidence 0.24 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1865555 Disease Relevance 0.70 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox